In the News

1857 News Items found
An MSK scientists works in the lab
MSK Research Highlights, August 13, 2024
New MSK research found patients with non-small cell lung cancer brain metastases may benefit from up-front stereotactic radiosurgery; identified a connection between antibiotic use and autoimmune diseases; and uncovered a previously unknown structural role for messenger RNAs in the cytoplasm of cells.
MSK neuro-oncologist Ingo Mellinghoff
A new drug could be an effective treatment for some people with low-grade glioma.
Dr. Sandra D'Angelo
In the Clinic
The FDA has approved an engineered cell therapy called afamitresgene autoleuecel (Tecelra®, also known as afami-cel) for treating advanced synovial sarcoma. The clinical trials resulting in the drug’s approval were led by Dr. Sandra D’Angelo of MSK.
MSK lab coat
A team of researchers led by Memorial Sloan Kettering Cancer Center (MSK) and collaborators at Emory University are shedding new light on deadly fungal infections that develop in bone marrow transplant patients.
MSK hematologic oncologist Lia Palomba talking to patient.
Article
Learn how MSK researchers led the way in the approval of a new mantle cell lymphoma CAR T cell treatment.
Detail shot of a scientist purifying proteins
MSK Research Highlights, July 31, 2024
New MSK research showed giving chemotherapy shortly after a stem cell or bone marrow transplant from a less than perfectly matched donor greatly reduces the chances that the patient will develop graft-versus-host disease (GVHD); and sheds new light on cell state changes in prostate cancer.
Grace Yang reclines in a hospital bed and holds a bag of stem cells.
Learn everything you need to know about donating bone marrow or blood stem cells and why it’s important to join a public registry.
Dr. Jun Mao performs acupuncture
Learn about the latest research on acupuncture from MSK and how our investigators are studying the benefits of acupuncture for relieving the side effects of cancer and its therapies.
Learn how exercise may affect the treatment of prostate cancer, in a first of its kind clinical trial at Memorial Sloan Kettering Cancer Center.
Andrea Schietinger
In order for immune cells to effectively kill cancer cells, a triad of three cells are necessary — a dendritic cell, a cytotoxic “killer” T cell, and a helper T cell, researchers at MSK and Baylor College of Medicine have found. The discovery could alter the way doctors administer immunotherapies.